← Back to headlines
Puma Biotechnology Forecasts NERLYNX Revenue and Plans Clinical Trials
Puma Biotechnology forecasts NERLYNX net product revenue of $202 million to $206 million in 2026, while also planning alisertib dose escalation and a new Lung2 trial.
8 May, 13:47 — 8 May, 13:47
Sources
Showing 1 of 1 sources
Related Stories
Amazon's First Customer Receipt Goes Viral, Bezos and Musk React
just now
Bacolod City Mayor Reconstitutes Task Force to Prevent ASF Outbreak
just now
Philippines' DOLE Urges Construction Sector to Adopt Progressive Wage Model
just now
Latvian Farmer Jānis Pīlēģis's Business and Community Involvement
1m ago